Last reviewed · How we verify
NCT06802848
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
trial testing Xeligekimab injection in Plaque Psoriasis in 1,000 participants. Not yet recruiting.
31 March 2026
Quick facts
| Lead sponsor | Chongqing Genrix Biopharmaceutical Co., Ltd |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 30 January 2025 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Xeligekimab injection — full drug profile →
Conditions studied
- Plaque Psoriasis — all drugs for Plaque Psoriasis →
- Psoriatic Arthritis — all drugs for Psoriatic Arthritis →
- Scalp Psoriasis — all drugs for Scalp Psoriasis →
- Nail Psoriasis — all drugs for Nail Psoriasis →
Sponsor
Chongqing Genrix Biopharmaceutical Co., Ltd
Who can join
18 and older, any sex, with Plaque Psoriasis or Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy. Despite the promising efficacy and safety shown in the phase III clinical trial, real-world data is needed to further support clinical decisions for this patient group. This study aims to evaluate the effectiveness and safety of xeligekimab in real-world clinical settings for adults with moderate to severe plaque psoriasis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06802848
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Xeligekimab injection
Trials testing the same drug.
- NCT07339566 — Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis · Phase 2, PHASE3 · not yet recruiting
Other recruiting trials for Plaque Psoriasis
Currently open trials in the same condition.
- NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
- NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
- NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
- NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
- NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06802848 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chongqing Genrix Biopharmaceutical Co., Ltd
- Last refreshed: 31 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06802848.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing